Three decades of volume change of a small greenlandic glacier using ground penetrating radar, structure from motion, and aerial photogrammetry

Glaciers in the Arctic are losing mass at an increasing rate. Here we use surface topography derived from Structure from Motion (SfM) and ice volume from ground penetrating radar (GPR) to describe the 2014 state of Aqqutikitsoq glacier (2.85 km2) on Greenland's west coast. A photogrammetrically derived 1985 digital elevation model (DEM) was subtracted from a 2014 DEM obtained using land-based SfM to calculate geodetic glacier mass balance. Furthermore, a detailed 2014 ground penetrating radar survey was performed to assess ice volume. From 1985 to 2014, the glacier has lost 49.8 ± 9.4 106 m3 of ice, corresponding to roughly a quarter of its 1985 volume (148.6 ± 47.6 106 m3) and a thinning rate of 0.60 ± 0.11 m a-1. The computations are challenged by a relatively large fraction of the 1985 DEM (∼50% of the glacier surface) being deemed unreliable owing to low contrast (snow cover) in the 1985 aerial photography. To address this issue, surface elevation in low contrast areas was measured manually at point locations and interpolated using a universal kriging approach. We conclude that ground-based SfM is well suited to establish high-quality DEMs of smaller glaciers. Provided favorable topography, the approach constitutes a viable alternative where the use of drones is not possible. Our investigations constitute the first glacier on Greenland's west coast where ice volume was determined and volume change calculated. The glacier's thinning rate is comparable to, for example, the Swiss Alps and underlines that arctic glaciers are subject to fast changes

Complex derivatives valuation: applying the Least-Squares Monte Carlo Simulation Method with several polynomial basis

Background: This article investigates the Least-Squares Monte Carlo Method by using different polynomial basis in American Asian Options pricing. The standard approach in the option pricing literature is to choose the basis arbitrarily. By comparing four different polynomial basis we show that the choice of basis interferes in the option's price. Methods: We assess Least-Squares Method performance in pricing four different American Asian Options by using four polynomial basis: Power, Laguerre, Legendre and Hermite A. To every American Asian Option priced, three sets of parameters are used in order to evaluate it properly. Results: We show that the choice of the basis interferes in the option's price by showing that one of them converges to the option's value faster than any other by using fewer simulated paths. In the case of an Amerasian call option, for example, we find that the preferable polynomial basis is Hermite A. For an Amerasian put option, the Power polynomial basis is recommended. Such empirical outcome is theoretically unpredictable, since in principle all basis can be indistinctly used when pricing the derivative. Conclusion: In this article The Least-Squares Monte Carlo Method performance is assessed in pricing four different types of American Asian Options by using four different polynomial basis through three different sets of parameters. Our results suggest that one polynomial basis is best suited to perform the method when pricing an American Asian option. Theoretically all basis can be indistinctly used when pricing the derivative. However, our results does not confirm these. We find that when pricing an American Asian put option, Power A is better than the other basis we have studied here whereas when pricing an American Asian call, Hermite A is better

Myeloproliferative and lymphoproliferative malignancies occurring in the same patient:a nationwide discovery cohort

Myeloid and lymphoid malignancies are postulated to have distinct pathogenetic mechanisms. The recent observation that patients with a myeloproliferative neoplasm have an increased risk of developing lymphoproliferative malignancy has challenged this assumption. We collected a nationwide cohort of patients with both malignancies. Patients diagnosed in 1990-2015 were identified through the national Danish Pathology Registry. We identified 599 patients with myeloproliferative neoplasm and a concomitant or subsequent diagnosis of lymphoma. Histopathological review of the diagnostic samples from each patient led to a final cohort of 97 individuals with confirmed dual diagnoses of myeloproliferative neoplasm and lymphoma. The age range at diagnosis was 19-94 years (median: 71 years). To avoid the inclusion of cases of therapy-induced myeloproliferative neoplasm occurring in patients previously treated for lymphoma, only patients with myeloproliferative neoplasm diagnosed unequivocally before the development of lymphoma were included. The average time interval between the diagnoses of the two malignancies was 1.5 years. In the majority of patients (90%) both diagnoses were established within 5 years from each other. Among the lymphoma entities, the frequency of peripheral T-cell lymphomas was markedly increased. Interestingly, all but one of the T-cell lymphomas were of angioimmunoblastic type. These findings suggest that myeloproliferative neoplasm and lymphoproliferative malignancy developing in the same patient may have common pathogenetic events, possibly already at progenitor level. We believe that the molecular characterization of the newly developed biorepository will help to highlight the mechanisms driving the genesis and clonal evolution of these hematopoietic malignancies

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia

Purpose Tyrosine kinase inhibitors (TKIs) have well-characterized immunomodulatory effects on T and NK cells, but the effects on the humoral immunity are less well known. In this project, we studied TKI-induced changes in B cell-mediated immunity. Methods We collected peripheral blood (PB) and bone marrow (BM) samples from chronic myeloid leukemia (CML) patients before and during first-line imatinib (n = 20), dasatinib (n = 16), nilotinib (n = 8), and bosutinib (n = 12) treatment. Plasma immunoglobulin levels were measured, and different B cell populations in PB and BM were analyzed with flow cytometry. Results Imatinib treatment decreased plasma IgA and IgG levels, while dasatinib reduced IgM levels. At diagnosis, the proportion of patients with IgA, IgG, and IgM levels below the lower limit of normal (LLN) was 0, 11, and 6% of all CML patients, respectively, whereas at 12 months timepoint the proportions were 6% (p = 0.13), 31% (p = 0.042) and 28% (p = 0.0078). Lower initial Ig levels predisposed to the development of hypogammaglobulinemia during TKI therapy. Decreased Ig levels in imatinibtreated patients were associated with higher percentages of immature BM B cells. The patients, who had low Ig levels during the TKI therapy, had significantly more frequent minor infections during the follow-up compared with the patients with normal Ig values (33% vs. 3%, p = 0.0016). No severe infections were reported, except recurrent upper respiratory tract infections in one imatinib-treated patient, who developed severe hypogammaglobulinemia. Conclusions TKI treatment decreases plasma Ig levels, which should be measured in patients with recurrent infections.Peer reviewe

Illness management and recovery (IMR) in Danish community mental health centres

<p>Abstract</p> <p>Background</p> <p>Schizophrenia and bipolar disorder are severe mental illnesses that can have a significant disabling impact on the lives of people. Psychosocial interventions that stress hope and recovery as a part of a multi-dimensional approach are possibly indicated to support people with severe mental illness in facilitating recovery. Illness Management and Recovery (IMR) is a curriculum-based psychosocial intervention designed as structured program with a recovery-oriented approach. The aim of IMR is to rehabilitate people with severe mental illnesses by helping them acquire knowledge and skills in managing their illness and achieve personal recovery goals. Previous randomised clinical trials indicate that IMR can be implemented with a good effect and a high fidelity though further trials are crucial to demonstrate the potential effectiveness of IMR.</p> <p>Methods/Design</p> <p>The trial design is a randomised, assessor-blinded, multi-centre, clinical trial of the IMR program compared with treatment as usual for 200 participants diagnosed with schizophrenia or bipolar disorder under the care of two community mental health centres in the Capital Region of Denmark. The primary outcome is level of functioning at the end of treatment. The secondary outcomes are disease symptoms; use of alcohol/drugs; individual meaning of recovery; hope; hospital admissions and out-patient psychiatric treatment at the end of treatment and the abovementioned and level of functioning at follow-up 21 months after baseline.</p> <p>Discussion</p> <p>If the results of this trial show IMR to be effective these positive results will strengthen the evidence of IMR as an effective comprehensive psychosocial intervention with a recovery-oriented approach for people with severe mental illness. This will have significant implications for the treatment and recovery of people with severe mental illness.</p> <p>Trial registration</p> <p>Registration number <a href="http://www.clinicaltrials.gov/ct2/show/NCT01361698">NCT01361698</a>.</p